OraSure Technologies Gets Emergency Use Authorization From FDA for New Ebola Test

By Kelly Cloonan

OraSure Technologies received emergency use authorization from the Food and Drug Administration for a new version of its ebola test.

The diagnostic testing company said Tuesday it received the authorization for its OraQuick Ebola 2.0 Rapid Antigen Test for use with whole blood in live patients, as well as cadaveric oral fluid from individuals suspected to have had ebola at the time of death.

The test can detect all four ebola viruses currently known to cause disease in humans, the company said.

OraSure's first generation OraQuick ebola test received marketing authorization from the FDA in 2019. The second-generation test has increased sensitivity, new chemistry and a more automated manufacturing process, the company said.

OraSure said the authorization comes amid an evolving ebola outbreak in central Africa.

"This outbreak is particularly challenging due to the Bundibugyo virus, which has no approved vaccine or targeted treatment, reinforcing the critical need for rapid, accurate diagnostics that can detect this virus and support timely containment efforts," Chief Executive Carrie Eglinton Manner said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

July 21, 2026 17:05 ET (21:05 GMT)